

1 **Fungal infections in Sudan: an underestimated health problem**

2

3 Sarah A. Ahmed<sup>1,2\*</sup>, Mawahib Ismail<sup>3</sup>, Mohamed Albirair<sup>4</sup>, Abdelsalam Mohamed Ahmed

4 Nail<sup>5,6\*</sup>, David W. Denning<sup>7</sup>

5

6 <sup>1</sup>Center of Expertise in Mycology Radboudumc / Canisius Wilhelmina Hospital, Nijmegen,

7 The Netherlands. ORCID: 0000-0003-0155-8113

8 <sup>2</sup>Foundation Atlas of Clinical Fungi, Hilversum, The Netherlands

9 <sup>3</sup>Mycology Reference laboratory, faculty of Medicine, University of Khartoum

10 <sup>4</sup>Department of Global Health, School of Public Health, University of Washington, Seattle,

11 WA, USA

12 <sup>5</sup>Tropical Diseases Teaching Hospital, Khartoum, Sudan

13 <sup>6</sup>Department of Internal Medicine, Faculty of Medicine and Health Sciences (OIU),

14 Khartoum, Sudan

15 <sup>7</sup>Manchester Fungal Infection Group, Manchester Academic Health Science Centre, University

16 of Manchester, Manchester, United Kingdom

17

18

19

20 \* Corresponding authors

21 [Sarah.AhmedIbrahim@radboudumc.nl](mailto:Sarah.AhmedIbrahim@radboudumc.nl) (SAA)

22 [abdelsalamnail@yahoo.com](mailto:abdelsalamnail@yahoo.com) (AMAN)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 **Abstract**

25 Fungal diseases are associated with high morbidity and mortality, yet their epidemiology and  
26 burden are not well addressed. While deaths probably exceed 1.5 million per year, many cases  
27 remain undiagnosed and underreported. Estimating the burden of these diseases is needed for  
28 prioritization and implementation of effective control programs. Here we used a model based  
29 on population at risk to estimate the burden of serious fungal infections in Sudan. The  
30 prevalence of the susceptible population including HIV, TB, cancer, asthma, and COPD was  
31 obtained from the literature. Incidence and prevalence of fungal infections were calculated  
32 using local data when applicable and if not available then regional or international figures were  
33 used. In total, the estimated number of Sudanese suffering from fungal disease is 5 M (10% of  
34 the total population). Tinea capitis, recurrent vulvovaginitis and keratitis are estimated to affect  
35 4,127,760, 631,261, and 6,552 patients, respectively. HIV-related mycosis is estimated to  
36 affect 5,945 oral candidiasis, 1,921 esophageal candidiasis, 571 *Pneumocystis* pneumonia, and  
37 462 cryptococcal meningitis cases. *Aspergillus* infections are estimated as follow: 3,438  
38 invasive aspergillosis, 14,950 chronic pulmonary aspergillosis, 67,860 allergic  
39 bronchopulmonary aspergillosis cases, while the prevalence of severe asthma with fungal  
40 sensitization and fungal rhinosinusitis was 86,860 and 93,600 cases, respectively. The  
41 neglected tropical disease eumycetoma was estimated to affect 16,837 cases with a rate of  
42 36/100,000. Serious fungal infections are quite common in Sudan and require urgent attention  
43 to improve diagnosis, promote treatment, and develop surveillance programs.

44

45

46

47

48

## 49 **Author Summary**

50 Fungal infections are present globally, but the burden is higher in sub-Saharan Africa. Many  
51 of these infections occur because of underline clinical conditions such as HIV, TB, cancer,  
52 asthma, and chronic obstructive pulmonary disease (COPD), while some may occur without  
53 underline conditions. We used the prevalence of susceptible populations to estimate the burden  
54 of fungal diseases in Sudan. Based on that, we found a total of 5 million Sudanese suffering  
55 from fungal infection. The most common disease was scalp infection (tinea capitis), followed  
56 by recurrent vulvovaginitis. Fungal eye infection was estimated to affect 6,552 patients, and  
57 the subcutaneous neglected tropical disease eumycetoma affects 16,837 individuals. We also  
58 reported a high burden for HIV- and TB-related mycoses. The study highlighted the need to  
59 develop surveillance programs for fungal infections in Sudan.

60

61

62

63

64

65

66

67

68

69

70

71

72

73

## 74 **Introduction**

75 The African continent has the highest prevalence of infectious diseases in the world leading to  
76 many years of life lost (YLL) and high disability-adjusted life years (DALYs) lived [1].  
77 Estimated deaths as a result of communicable diseases in 2019 was 4.1 million. The high death  
78 rate is mainly attributed to human immunodeficiency virus (HIV), respiratory infections,  
79 malaria and tuberculosis (TB) among others [2]. Malnutrition, poverty, and illiteracy are the  
80 main drivers, as 34 out of 54 African countries are classified as low or lower middle income  
81 countries [3]. Of the total global HIV and TB cases, 75% and 25% are found in Sub-Saharan  
82 Africa, respectively [4, 5]. With the introduction of antiretroviral therapy and national TB  
83 programs in many countries, the control of these infections has remarkably improved.  
84 However, mortality remains high mainly because of other comorbid conditions such as fungal  
85 infections [6]. Around 50% of opportunistic infections affecting HIV individuals are thought  
86 to be caused by fungi. Cryptococcal meningitis and *Pneumocystis* pneumonia are the most  
87 common AIDS-related mycotic diseases with an annual reported incidence of 220,000 and  
88 400,000 respectively [7, 8]. Patients with pulmonary TB are at moderate risk for the  
89 development of chronic pulmonary aspergillosis (CPA), with an estimated prevalence of ~3  
90 million cases [9]. Notably, a large proportion of these infections occur in Africa [10]. Despite  
91 the high burden of fungal diseases in Africa and worldwide, they have received little attention  
92 by healthcare organizations. That is mainly because mycotic infections are challenging in terms  
93 of diagnosis, treatment and control [11].

94 Fungal infections in humans are mainly caused by about 30 species of fungi, with a  
95 large diversity of other species as occasional pathogens or allergens. Infections range from  
96 superficial affecting skin, hair, and nail to deep systemic and invasive conditions [12]. Invasive  
97 infections are generally caused by a few species and occur mainly in patients with underlying  
98 diseases or under immunosuppressive medications [11]. In such patients, the most commonly

99 reported fungi are *Candida*, *Pneumocystis jirovecii*, *Cryptococcus*, and *Aspergillus*, with other  
100 important potentially lethal opportunists including *Mucorales*, *Histoplasma*, *Talaromyces*, and  
101 *Emergomyces* [12]. Patients with cystic fibrosis, chronic lung diseases or anatomically  
102 impaired lungs are at risk of infection by many fungal species, mainly *Aspergillus*. Serious  
103 cutaneous or subcutaneous infections include sporotrichosis, chromoblastomycosis,  
104 mycetoma, and phaeohyphomycosis [12].

105 In recent years, efforts have been made by Global Action for Fungal Infections (GAFFI,  
106 <https://gaffi.org/>) and the Leading International Fungal Education (LIFE,  
107 <https://www.fungaleducation.org/>) to estimate the burden of fungal diseases both globally and  
108 in many countries in the world. In Africa, and for the first time, the burden of mycotic diseases  
109 has been studied and estimated for about 23 countries [13]. In all these studies, reliable data on  
110 fungal infections are limited or unavailable, particularly for entities other than cryptococcosis.  
111 In addition, the estimated incidence and prevalence of fungal diseases was found to be much  
112 higher than previously assumed or reported. For example, studies have shown that, around 8%  
113 of the Ethiopian population and 11.5% of Eritrean population suffer annually from serious  
114 fungal infections [14, 15]. Of these infections, cryptococcal meningitis, *Pneumocystis*  
115 pneumonia and aspergillosis are the most frequent potentially lethal conditions. However,  
116 reported cases attributed to these fungi in countries like Ethiopia or Eritrea are few.

117 The Republic of Sudan, located in Northeast Africa, is bordered by Egypt, Eritrea,  
118 Ethiopia, South Sudan, Central African Republic, Chad and Libya. With a total area of  
119 1,882,000 km<sup>2</sup>, the country is the third largest country in Africa. It has been independent since  
120 1956 and to date, Sudan has suffered internal conflict, civil war, and political instability. More  
121 than half of the population resides in rural areas and around 46% live below the line of poverty  
122 [16]. Sudan is endemic with mycetoma with more than 7,000 cases reported by the Mycetoma  
123 Research Center (MRC) in Khartoum [17]. Despite that, mycetoma has been badly neglected

124 for many decades and only after the advocacy of MRC and mycetoma consortium was the  
125 disease has been added to the World Health Organization (WHO) list of Neglected Tropical  
126 Diseases (NTDs) along with chromoblastomycosis and sporotrichosis [18]. In the present  
127 study, we aimed to investigate the burden of serious fungal diseases in Sudan and provide a  
128 clear view of the mycotic diseases profile in the country.

129

## 130 **Methods**

131 The basis of our estimates is the use of appropriate denominators of at-risk populations and  
132 applying numerators for different fungal diseases. We sourced total population and the number  
133 of children (<15 years) from the CIA fact book [19]. To estimate chronic obstructive pulmonary  
134 disease (COPD), we used the ratio of those over 40 years to the total from UN estimates for  
135 2020 [20]. We took data about HIV prevalence, proportion on antiretroviral therapy (ART),  
136 and AIDS-related deaths from UNAIDS for 2020 [21]. We calculated the proportion at risk of  
137 opportunistic fungal infections by assuming a 7-year decline in CD4 counts to  $<200 \times 10^6$   
138 combined with an average of 11% failing ART [22]. Pulmonary TB was taken from the WHO  
139 Global tuberculosis report 2020 [23]. We assumed a 10% rate of asthma in adults, taken from  
140 the 2003 World Health Survey in Ethiopia [24]. Unpublished data indicates a 16% prevalence  
141 of COPD in those over 40 years [25] and we have assumed a 10.5% admission to hospital (or  
142 equivalent healthcare contact) for exacerbations. Lung cancer and acute leukaemia for 2020  
143 were taken from the International Agency for Research on Cancer [26] and the acute myeloid  
144 leukaemia rate from the WHO estimates for low-income countries (2.5/100,000) [27]. Annual  
145 renal transplantation procedures for 2020 (possibly lowered by COVID-19) were taken from  
146 the International Registry on Organ Donation and Transplantation [28].

147 For the prevalence and incidence of fungal disease in Sudan, we searched PubMed,  
148 Web of Science and Google Scholar databases. We also searched scientific repositories and

149 health reports published by national and international professional organizations. The initial  
150 search was performed using the term “Sudan” and “fungal infection” or “Sudan” and  
151 “mycosis”. We searched the databases for individual fungal disease and underline risk groups.  
152 If no data was available, we calculated the burden using regional or international figures.

153

## 154 **Results**

155 In 2021, the estimated population of Sudan was 46.8 million; of them 42% were children and  
156 20% were adults over 40 years [19] (Table 1). According to the World Bank data, Gross  
157 Domestic Product (GDP) per capita in Sudan is around 764.3 US\$ [29]. The public health  
158 infrastructure in the country is underdeveloped with a very low health expenditure of only 1.15  
159 % GDP. There are only 1.6 primary health care facilities and 6.7 hospital beds per 10,000  
160 population. Low wages and income instability have resulted in high attrition of Sudanese  
161 medical staff leaving only 4.1 physicians and 8.3 nurses per 10,000 inhabitants [30, 31].

162

163 **Table 1. Demographic data and the population at risk for fungal infections in Sudan.**

Data	Number	Comment	Reference
Population	46.8 million	2021	[19]
Children 0-14	19.7 million	42% of the population	[19]
Adults over 40 years	9.36 million	20% of the population	[20]
HIV/infection	49,000	Prevalence of HIV/AIDS 2020	[21]
Pulmonary TB	28,000	Annual incidence 2020	[23]
Asthma in adults	10%	Taken from Ethiopia (2003)	[24]
COPD patients	1,360,800 – 2,214,950	Population, 3.5%, extrapolated from Egypt, 16% of >40 years unpublished data from Sudan	[25, 32]

COPD hospital admissions	142,900 – 232,570	10.5% annually, extrapolated from Algeria	[33]
Lung cancer	647	1.4/100 000 incidence 2020	[26]
Acute leukaemia	1,297	2.7/100,000 incidence	[27]
Renal transplantation	139	2020	[28]

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

Among the sub-Saharan African countries, Sudan is considered to be one of the lowest HIV-burden countries with an estimated prevalence among adults of 0.1% in 2020. Of the estimated 49,000 people living with HIV (PLHIV) in 2020 only 18,000 knew their status and 12,000 were on antiretroviral therapy, while the estimated death is about 2,300 [21]. Although invasive fungal diseases on the global scale contribute to about 50% of AIDS-related death annually [22], no available data on fungal disease related death in HIV patients in Sudan. Therefore, we estimated the burden based on figures from other studies [8, 34, 35]. We estimated the annual incidence of AIDS related fungal diseases in Sudan to be: 462 cases of cryptococcal meningitis, 571 cases of *Pneumocystis* pneumonia, 1,921 of oesophageal candidiasis, and 5,945 of oral candidiasis. Although histoplasmosis is an AIDS defining disease and has been reported to coexist with TB/HIV in sub-Saharan countries [36], we could only find two case reports [37, 38].

In addition to HIV, respiratory diseases such as COPD and cancer are among the risk factors for the development of invasive aspergillosis [39]. The prevalence of COPD in Sudan was found to be 16% in those over 40 years of age, and the annual incidence of lung cancer and acute leukemia was 647 and 1,297 cases, respectively [26, 27]. We assumed that 13% of cases of acute myeloid leukaemia develop invasive aspergillosis [40], and an equal number of cases in other leukaemias and lymphomas [35, 40], also that 4% of HIV deaths are linked to



184 invasive aspergillosis [41]. Based on this data, we have estimated the overall annual incidence  
185 of invasive aspergillosis to be 3,438 cases (35 per 100,000).

186 Closely linked to malnutrition and poverty, TB remains one of the major health issues  
187 in Sudan with an infection rate of 63 per 100,000 population and a mortality rate of 9.81 per  
188 100,000 population [23]. Some patients with negative tests for TB are included in these figures,  
189 and some will have alternative diagnoses such as chronic pulmonary aspergillosis (CPA). After  
190 treatment for pulmonary TB, lung cavitation develops in 20% to 40% of patients. This leads to  
191 colonization by *Aspergillus* species and in some the subsequent development of CPA [42]. We  
192 estimated CPA following TB infection in Sudan using the recently published model for India,  
193 and data from Africa [43, 44]. CPA cases which are mistaken for, are co-infections with or  
194 occur in the months after therapy for TB are estimated at 3,359 cases annually, of whom around  
195 359 die, accounting for 11.7% of TB all deaths. The cumulative prevalence of CPA including  
196 those cases and those occurring post TB cure over 5 years is estimated at 14,950 cases.

197 A community-based survey on asthma conducted in 4 cities in Sudan estimated the  
198 prevalence of the disease in adults to be around 10% [45]. A slightly higher prevalence of  
199 12.5% has been reported in children [46], and under-diagnosis is very common [47]. Allergic  
200 bronchopulmonary aspergillosis (ABPA) occurs mostly as a complication of asthma and other  
201 diseases affecting respiratory function such as cystic fibrosis (CF) [48]. In Sudan, cystic  
202 fibrosis is relatively rare and only 35 cases have been reported [49]. The 2,714,400 adults living  
203 with asthma in Sudan are probably at risk of ABPA, and to estimate the burden we assume that  
204 2.5% develop ABPA according to studies conducted in South Africa, Saudi Arabia and Uganda  
205 [50-52]. The likely prevalence of ABPA in Sudan can then be calculated as 67,860 (145 per  
206 100,000). The severity of asthma usually increases in those with sensitization by *Aspergillus*  
207 or other fungi and has been reported in 42% of Ugandan adults with asthma [52]. To estimate  
208 the burden of severe asthma with fungal sensitization (SAFS), we assume that severe asthma

209 occurs in 20% of the total asthmatic population and of those, 16% have SAFS. Thus, the  
210 prevalence of SAFA in Sudan is conservatively estimated at 86,860 cases (191 per 100,000).  
211 There may be some overlap between ABPA and SAFS, but patients with allergic  
212 bronchopulmonary mycosis [52] have been omitted from the estimates.

213         Depending on the infected host, the clinical presentation of fungal rhinosinusitis can  
214 range from allergic to granulomatous or invasive and life threatening. The prevalence of the  
215 allergic rhinosinusitis ranges from 10% to 40% and of these 5% are assumed to be caused by  
216 fungi and we have used a 2% rate [53, 54]. Accordingly, we estimated that allergic and  
217 granulomatous rhinosinusitis in Sudan possibly affect as many as 93,600 people, a prevalence  
218 of 200 per 100,000. Veress et al. [55] studied 46 cases of granulomatous sinusitis from Sudan  
219 due to *Aspergillus*. Additionally, in around 4 years, Ahmed and Osman [56] reported their  
220 experience with 440 cases of fungal rhinosinusitis from two centers in Khartoum. Furthermore,  
221 of the 579 nasal biopsy samples studied by Mahgoub et al. [57], 280 were positive for fungi,  
222 and at least eight patients were diagnosed with chronic invasive fungal sinusitis [57].

223         Candidemia and *Candida* peritonitis are particularly serious infections affecting  
224 critically ill patients, such those in ICU. We couldn't find data on these infections in Sudan.  
225 Internationally, the incidence of candidemia has been estimated to occur in 2 to 21 per 100,000  
226 [10]. We have applied a low international figure (5 per 100,000) to determine the annual  
227 incidence in Sudan, a total of 2,340 cases. *Candida* peritonitis in surgical patients is estimated  
228 to infect 351 cases per year if we assume that 33% of candidemia cases are ICU patients and  
229 50% of them might develop *Candida* peritonitis [58].

230         Globally, around 138 million women are affected yearly by recurrent vulvovaginal  
231 candidiasis (rVVC), occurring at least 4 episodes per year, and the prevalence among African  
232 women is 33% [59]. In Sudan, Kafi et al. [60] reported a prevalence of 10.1%, while in pregnant  
233 women who are at higher risk, the reported prevalence was 16.6% and 32.6% according to

234 Nemery et al. [61] and Abdelaziz et al. [62], respectively. In general, women in the age bracket  
235 of 15-50 years are at risk of rVVC. Using a conservative 6% proportion on this age group [63],  
236 around 631,300 Sudanese women are probably affected by rVVC (2698 per 100,000).

237 Cases of entomophthoramycosis were reported from Sudan: 10 cases of  
238 basidiobolomycosis and one caused by *Conidiobolus* spp. [64-67]. The latter case was an  
239 immigrant from Sudan who was diagnosed one month after arrival in Switzerland. For  
240 mucormycosis, we estimated an annual incidence of 94 cases with an infection rate of 0.2 per  
241 100,000 population, based on data from France [68].

242 Sudan is an endemic region for mycetoma; the incidence in a single endemic village  
243 was found to be 14.5 per 1,000 inhabitants [69]. This long-standing and disabling disease  
244 carries a significant burden to each patient and their community. About 86% (5,819) of the  
245 mycetoma patients reported by the MRC had have the infection for nearly 10 years. Yet, the  
246 exact prevalence of the disease in Sudan is unknown. Abbott reported a total of 1,231 patients  
247 admitted to Sudanese hospitals in a period of 2.5 years [70]. Using a geostatistical model,  
248 Hassan et al. [71] estimated the burden of the disease over 28 years to be 51,541 cases. Based  
249 on that, we calculate a total of 1,841 new cases annually. Assuming a 2% annual mortality and  
250 an infection duration of 10 years, we estimate an annual total of 16,837 prevalent cases, with a  
251 prevalence of 36 per 100,000. For other implantation mycosis: we did not find any report for  
252 chromoblastomycosis and only found two cases of sporotrichosis in the literature [72].

253 Tinea capitis was reported in 3.22% of school children in Sudan [73]. More recent data  
254 from the Eastern part of the country showed a prevalence of 17% [74]. We estimated the  
255 prevalence from the total number of children who are risk of infection using 19%, and probably  
256 4,127,760 are affected [75].

257           For fungal keratitis, we could not find epidemiologic data from Sudan. Therefore, we  
258    estimated the burden based on the data from Egypt as 14 per 100,000 individuals which gave  
259    an annual incidence of 6,550 patients [76].

260

261

262    **Table 2. Estimated burden of serious mycotic infections in Sudan**

Serious Fungal Infection	Underline disorder							Reference
	None	HIV/AIDS	Respiratory	Cancer	Critical care & Surgery	Totals	Prevalence /100,000	
Cryptococcal meningitis		462				462	0.99	[8]
<i>Pneumocystis</i> pneumonia		571				571	1.22	[35]
Invasive aspergillosis		92	3040	306		3438	7.35	[39, 77]
Chronic pulmonary aspergillosis			14,950			14,950	31.94	[43, 44]
Allergic bronchopulmonary aspergillosis			67,860			67,860	145	[48]
Severe asthma with fungal sensitisation			86,860			86,860	191	[50-52]
Allergic and granulomatous fungal rhinosinusitis	93,600					93,600	200	[53, 54]
Candidaemia				1638	702	2340	5	[10]
Candida peritonitis					351	351	0.75	[58]
Oral candidiasis		5945				5945	12.7	[78]
Oesophageal candidiasis		1921				1921	4.1	[34, 79]
Recurrent Candida vaginitis ( $\geq 4x/year$ )	631,300					631,300	2698	[63]
Mucormycosis				94		94	0.2	[68]
Mycetoma	1840					16,837	36	[71]
Fungal keratitis	6550					6550	14	[76]
Tinea capitis	4,127,760					4,127,760	8820	[75]
Total serious fungal infection burden						<b>5,060,792</b>		

## 264 Discussion

265 Like other African developing countries, Sudan suffers from an excessive burden of both  
266 communicable and non-communicable diseases [30]. In the present study, and for the first time,  
267 the burden of serious fungal infections in Sudan is investigated. According to our results,  
268 around 5 million Sudanese are suffering from fungal diseases; representing 10% of the total  
269 population (Table 2). Though very high, the burden is similar to that reported from Ethiopia,  
270 but higher than Egypt [14, 76]. That is mainly because these estimates were based on the  
271 population at risk, and therefore variability between countries is anticipated. Furthermore,  
272 Sudan and Ethiopia are low-income countries sharing similar economic conditions while Egypt  
273 is lower middle-income country.

274 The most prevalent fungal infection in Sudan based on our estimates is tinea capitis, a  
275 superficial disease caused by dermatophytes and primarily affects children of school age.  
276 Dermatophytoses are the most common fungal infections worldwide infecting around 20%-  
277 25% of the world's population [80]. In Africa, around 138.1 million children suffer from tinea  
278 capitis, which is around one out of every five children [75]. Thus, our estimates of 4,127,760  
279 case in Sudan is not surprising and is close to what has been reported in other Sub-Saharan  
280 countries [75]. Furthermore, tinea capitis is highly contagious infection; of the 117 patients  
281 studied by Magzoub et al. and attended Khartoum Dermatological Hospital, 82.9% reported a  
282 history of contact with infected patients [81]. Unlike skin and nail dermatophytosis, scalp  
283 infection is a morbid condition that requires prolonged antifungal medication and might cause  
284 inflammation resulting in permanent hair loss. The British Association of Dermatologists  
285 recommends the use of terbinafine for treating infections by *Trichophyton* and griseofulvin for  
286 treating cases of *Microsporum* spp. [82]. Therefore, optimal diagnosis should not only be made  
287 by direct microscopy, but also by culture to allow species identification. In Sudan, direct

288 microscopy is performed occasionally in specialized laboratories and culture is rarely  
289 performed [83] (Table 3).

290 Fungal keratitis is a potentially blinding condition that annually affects over 1 million  
291 individuals from all over the world [84]. The burden is however higher in tropical and  
292 subtropical areas; in a study from East Africa, fungal keratitis accounted for 25% of the total  
293 microbial keratitis, and in Egypt it was 55% [85, 86]. Of the 64,529 Sudanese patients studied  
294 by Lakho et al. [87], 1279 (3.8%) had an eye infection, but the type of microorganism was not  
295 determined. To estimate the burden in Sudan, we applied the estimates from Egypt (14 per  
296 100,000) [76]. Mycotic keratitis is considered an ophthalmic emergency requiring rapid  
297 intervention to prevent ocular morbidity and eye loss. Detection of fungal elements in the  
298 corneal scraping followed by culture are the gold standard diagnostic procedures [84]. In  
299 Sudan, fungal culture is rarely performed, and direct microscopy of corneal scraping is only  
300 available in limited situations (Table 2). Fungal culture is needed to identify the etiology: more  
301 than 100 species of fungi are reported to cause fungal keratitis, among them is the multidrug  
302 resistant *Fusarium* spp. [84]. Natamycin eye drops, a drug that was added to the WHO list of  
303 essential medicines in 2017 is the first line antifungal therapy for treating fungal keratitis [88].  
304 Nevertheless, based on GAFFI's surveys, this drug is not available in many countries in the  
305 world including Sudan [89]. Most of the cases estimated in our study probably have gone  
306 undiagnosed or not received proper treatment. With the current lack of diagnosis and treatment  
307 of fungal keratitis globally, scientists have called for the disease to be added to the WHO list  
308 of neglected tropical diseases [84].

309 Sudan is the country where the highest number of mycetoma cases are present; the  
310 country is described as the disease homeland. The first report of mycetoma in Sudan is back to  
311 the 18<sup>th</sup> century, yet diagnosis and treatment remain challenging. In 1991, the MRC was  
312 established in Khartoum to provide medical care for the patients and to promote research [17].

313 After the recognition of mycetoma as a neglected tropical disease, the MRC has officially  
314 become a WHO Collaborating Center. Recently, researchers from the center have tried to  
315 estimate the burden of the disease for a period of 28 years; the overall number of people who  
316 have been suffering from mycetoma was 63,825 cases of which eumycetoma accounted for  
317 51,541 (81%) cases [71]. However, comprehensive epidemiologic data on mortality or DALY  
318 expectancy related to this disabling condition is currently unavailable. Eumycetoma prevalence  
319 based on our study was 36 per 100,000. This rate is remarkably high, and the burden of other  
320 serious fungal diseases estimated in the present study are high too. For example, pulmonary  
321 aspergillosis (CPA and IA) affects 18,338 individuals, and fungal keratitis affect 6,552; both  
322 infections require extensive diagnostic procedures and antifungal therapy but are not on the list  
323 of the WHO of neglected diseases. Thus, not only mycetoma, but other serious fungal diseases  
324 are neglected too.

325

326

327

328

329

330

331

332 **Table 3:** Availability of laboratory diagnostic methods and antifungal medications for fungal  
333 infections in Sudan [90]



<b>Fungal Infection</b>	<b>Laboratory diagnostic tests</b>							<b>Treatment</b>			
<b>Cryptococcal meningitis</b>	Microscopy with India ink				Cryptococcus antigen test		Culture	Amp B + 5-FC		FCZ + 5-FC	
<b><i>Pneumocystis pneumonia</i></b>	Direct microscopy (stained smear)				Immunofluorescent stain	PCR	Histology	Co-trimoxazole	Clindamycin + Primaquine	Dapsone + Trimethoprim	
<b>Aspergillosis (IA + CPA)</b>	Direct microscopy	Direct microscopy (fluorescence)	Culture	Asp. PCR	Histology	GM Antigen	Antibody serology	VCZ	Amp B	Echinocandins	
<b>Fungal rhinosinusitis</b>	Direct microscopy	Direct microscopy (fluorescence)		Culture	Histology	Antibody serology		ITZ	VCZ	other azoles	Amp B
<b>Candidaemia</b>	Blood culture				1,3-β-D-glucan			Echinocandin	Amp B	VCZ	FCZ
<b>Candida vaginitis</b>	Direct microscopy (smear)			Direct microscopy (wet preparation)				Topical azoles		FCZ	
<b>Mucormycosis</b>	Direct microscopy (fluorescent)			Culture			Histology	Amp B	PCZ	ISZ	
<b>Mycetoma</b>	Direct microscopy	Culture	Histology					ITZ		VCZ	
<b>Fungal keratitis</b>	Direct microscopy				Direct microscopy (fluorescence)		Culture	Natamycin	Amp B	Econazole eye drops	VCZ eye drops
<b>Tinea capitis</b>	Direct microscopy				Direct microscopy (fluorescence)		Culture	Griseofulvin	Terbinafine	ITZ	

334 Asp. PCR *Aspergillus* PCR, GM Galactomannan, Amp B amphotericin B, ITZ itraconazole, VCZ voriconazole, PCZ posaconazole, ISA isavuconazole, 5-flucytosine  
335 5-FC, Fluconazole FCZ. Green cells: frequently available, Red cells: unavailable, Grey cells: limited availability.

336           Although our estimates showed a high burden of fungal infections in immunocompetent  
337 individuals, we also have found a high burden in patients with underlying disorders that are  
338 more susceptible or at risk for opportunistic fungal diseases. Among the most affected  
339 population are HIV/AIDS and TB patients. In Sudan, the number of HIV cases is relatively  
340 low, but tuberculosis is remarkably high. In 2020, around 28,000 Sudanese were infected by  
341 *M. tuberculosis*, and this number will probably increase as a result of current conflict and  
342 economic instability [91]. Survivors of TB may develop CPA in 6.5% of individuals with  
343 remaining cavities, each year, and a significant minority of those thought to have pulmonary  
344 TB with negative tests probably have CPA [43]. Globally, CPA is thought to affect around 3  
345 million individuals of whom 1.2 million are post-TB [44]. In Sudan, despite the large number  
346 of TB infected individuals, CPA is rarely diagnosed. In 1972, Mahgoub and Elhassan reported  
347 a case of pulmonary aspergillosis with cavitation, probably representing CPA [92].  
348 Furthermore, *Aspergillus* spp. was isolated from 9 out of 150 TB patients studied by Baraka et  
349 al. in Khartoum [93]. According to our estimates around 3,000 TB survivors are affected by  
350 CPA annually. This is similar to what has been reported in Ethiopia, a country with a high  
351 burden of TB like Sudan [14]. CPA is associated with a high mortality rate; estimated to be  
352 1,338 annually in the current study (data not shown). Thus, patients with persistent pulmonary  
353 symptoms but smear negative should be screened for CPA; presence of cavities in X-ray  
354 combined with serology or direct detection and isolation of *Aspergillus* from respiratory  
355 samples are the main diagnostic criteria [94]. Surprisingly, the above-mentioned tests might be  
356 available in Sudan, but the detection rate of CPA patients is extremely low. That is likely due  
357 to the inadequate awareness of physicians and healthcare professionals. During the period of 4  
358 years, the mycology reference laboratory in Khartoum received only 713 sputum samples from  
359 patients with suspected fungal infections. Underlying diseases in those patients were not only  
360 TB, but also other respiratory conditions such as asthma [95].

361 Fungal allergy (sensitization) and airways infection affect asthmatic patients and are usually  
362 manifest as SAFS and ABPA (otherwise known as ‘fungal asthma’), with some overlap  
363 between the two conditions. Fungal asthma is usually linked to poorly controlled asthma and  
364 responsive to antifungal therapy [96]. Our estimate for SAFS is 86,860 and for ABPA is  
365 67,860, placing them as the fourth most common fungal diseases in Sudan. Compared to other  
366 neighboring countries, these estimates are relatively lower than in Egypt, but similar to the  
367 Democratic Republic of Congo [76, 97]. In Sudan, asthma is among the top 10 cause of  
368 hospitalization, and the rate of uncontrolled disease is very high reaching up to 84.5%  
369 according to a recent study from Osman et al. [98].

370 In general, the prevalence of asthma and other respiratory diseases such as COPD in  
371 Africa is high, particularly in the sub-Saharan countries. Among the main risk factors are  
372 tobacco smoking and air pollution resulting from the use of unprocessed biomass fuels. Around  
373 90% of rural population in Africa rely on biomass fuels for cooking, and that holds true for  
374 Sudan, as half of Sudanese population reside in rural area [99]. The estimated prevalence of  
375 COPD in Sudan is 2,214,950 cases of whom 232,570 are probably hospitalized, annually [25].  
376 Those patients are at risk of invasive aspergillosis; we estimated an annual incidence of 3,040  
377 cases of IA in COPD patients. This needs further study. Invasive aspergillosis also affects  
378 patients with malignancies, transplantation, and AIDS. With the emergence of COVID-19,  
379 another population has become at risk of infection [100]. Invasive infections by *Aspergillus* are  
380 generally associated with high morbidity and mortality. Therefore, WHO placed *Aspergillus*  
381 *fumigatus* among the critical group in the priority list of pathogenic fungi [101]. A consensus  
382 guideline for the treatment of invasive aspergillosis recommends the use of voriconazole as  
383 first line therapy or, if not available, then isavuconazole, posaconazole, amphotericin B or an  
384 echinocandin [102]. Unfortunately, all these drugs are not available in Sudan and of all the  
385 azoles only itraconazole and fluconazole are available [89] (Table 3).

386 According to UNAIDS, deaths from AIDS-related illness in Sudan in 2021 were 2,300,  
387 of which fungal infections are probably among the major causes. Every year, around 135,000  
388 people in sub-Saharan Africa lose their life because of cryptococcal meningitis [8]. We  
389 estimated the annual number of new cases of CM and PCP among adult HIV/AIDS in Sudan  
390 to 462 and 571, respectively. These estimates are considerably low compared to other countries  
391 in Africa [8, 14]. We did not estimate the burden in non-HIV populations. Nevertheless, we  
392 could not find a single report from Sudan for the two diseases in both HIV and non-HIV  
393 individuals. That is probably due to the lack of diagnostic methods in the country. Lumbar  
394 puncture is rarely performed and cryptococcal capsular antigen (CrAg) test is not available  
395 either (Table 3). Detection of *P. jirovecii* in induced sputum or bronchoalveolar lavage from  
396 suspected cases is the gold standard procedure for the diagnosis of PCP [103]. Microscopy is  
397 simple without requiring sophisticated instruments although *Pneumocystis* PCR is more  
398 sensitive [103]. However, the lack of awareness and training among the physicians and  
399 laboratory personnel is probably the main reasons for under-reporting and under recognition of  
400 cases. Of note that CM, PCP, and histoplasmosis are increasingly reported in Africa [104, 105].  
401 A recent study from Nigeria found that 7.7% of HIV patients with low CD4 counts tested  
402 positive for *Histoplasma* antigen [104]. In Sudan, there are probably more cases of *Histoplasma*  
403 than the two cases of African histoplasmosis reported in 1988 and 2008 [37, 38].

404 *Candida* and *Candida*-like yeasts are among the most common cause of fungal  
405 infections globally. Invasive candidiasis is associated with high economic burden and high  
406 mortality rate - up to 50% [58]. Based on our estimates, *Candida* related infections are the  
407 second most common fungal infections in Sudan. Although mostly mucocutaneous, we  
408 estimated candidemia in around 2300 individual every year. The recommended antifungal  
409 therapy for candidemia in neutropenic and critically ill patients is echinocandins which is  
410 unavailable in Sudan, but fluconazole is available (Table 3) [89]. Prior to the antifungal

411 therapy, identification of the yeast down to the species level is paramount especially after the  
412 emergence of the multi-drug resistant *C. auris*, a species causing outbreaks in many countries  
413 of the world and has been reported from Sudan [106].

414 In general, for most of the mycotic diseases that are probably present in Sudan,  
415 diagnostic methods are lacking, and this could explain the scarcity of published data on these  
416 infections (Table 3). Nevertheless, we were able to estimate the burden using data and models  
417 utilized to study fungal diseases in other countries. Indeed, our estimates might not reflect the  
418 real situation, but they give some perspective on a high burden of some fungal diseases in the  
419 country. For example, it is unlikely that there are no cases for cryptococcosis, PCP or  
420 pulmonary aspergillosis are present in the Sudan, given with the substantial number of  
421 asthmatic, TB and HIV patients. Thus, obviously fungal diseases are badly neglected and  
422 require attention by healthcare authorities. There is an urgent need for campaigns to increase  
423 the awareness, promote research, and develop national surveillance program. Healthcare and  
424 academic institutions should take initiative by developing research and provide training for  
425 medical staff. Of note, there is a mycology reference laboratory in Khartoum located at the  
426 National Public Health Laboratory and run by the Faculty of Medicine, University of  
427 Khartoum. Such laboratories must be sufficiently well equipped to meet the requirement for  
428 diagnosis of fungal diseases.

429 In conclusion, the burden of serious fungal infections in Sudan has been estimated.  
430 Remarkably, of every 100,000 Sudanese women 2,698 suffer from recurrent *Candida* vaginitis.  
431 In addition, the 6,552 patients suffering from fungal keratitis are probably at risk of blindness  
432 in the absence of proper diagnosis and antifungal therapy. Awareness of morbidity and  
433 mortality of mycotic diseases need to be addressed urgently. Furthermore, local epidemiologic  
434 data is needed to validate the estimated burden and to provide more precise figures for the  
435 diseases in the country.

436 **References**

- 437 1. Coates MM, Ezzati M, Robles Aguilar G, Kwan GF, Vigo D, Mocumbi AO, et al.  
438 Burden of disease among the world's poorest billion people: An expert-informed secondary  
439 analysis of Global Burden of Disease estimates. PLoS One. 2021;16(8):e0253073. Epub  
440 20210816. doi: 10.1371/journal.pone.0253073. PubMed PMID: 34398896; PubMed Central  
441 PMCID: PMC8366975.
- 442 2. World Health Organization (WHO). WHO methods and data sources for country-  
443 level causes of death 2000-2019 2020 [cited 2023 01-03-2023]. Available from:  
444 [https://cdn.who.int/media/docs/default-source/gho-documents/global-health-](https://cdn.who.int/media/docs/default-source/gho-documents/global-health-estimates/ghe2019_cod_methods.pdf)  
445 [estimates/ghe2019\\_cod\\_methods.pdf](https://cdn.who.int/media/docs/default-source/gho-documents/global-health-estimates/ghe2019_cod_methods.pdf).
- 446 3. Boutayeb A. The Impact of Infectious Diseases on the Development of Africa.  
447 Handbook of Disease Burdens and Quality of Life Measures. 2010:1171-88.
- 448 4. Kharsany AB, Karim QA. HIV Infection and AIDS in Sub-Saharan Africa: Current  
449 Status, Challenges and Opportunities. Open AIDS J. 2016;10:34-48. Epub 20160408. doi:  
450 10.2174/1874613601610010034. PubMed PMID: 27347270; PubMed Central PMCID:  
451 PMC84893541.
- 452 5. Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, et al. Global  
453 Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention  
454 efforts. Int J Infect Dis. 2021;113 Suppl 1(Suppl 1):S7-S12. Epub 20210311. doi:  
455 10.1016/j.ijid.2021.02.107. PubMed PMID: 33716195; PubMed Central PMCID:  
456 PMC8433257.
- 457 6. Jarvis JN, Boulle A, Loyse A, Bicanic T, Rebe K, Williams A, et al. High ongoing  
458 burden of cryptococcal disease in Africa despite antiretroviral roll out. AIDS.  
459 2009;23(9):1182-3. doi: 10.1097/QAD.0b013e32832be0fc. PubMed PMID: 19451796;  
460 PubMed Central PMCID: PMC842871312.

- 461 7. Oladele R, Ogunisola F, Akanmu A, Stocking K, Denning DW, Govender N.  
462 Opportunistic fungal infections in persons living with advanced HIV disease in Lagos,  
463 Nigeria; a 12-year retrospective study. *Afr Health Sci.* 2020;20(4):1573-81. doi:  
464 10.4314/ahs.v20i4.9. PubMed PMID: 34394217; PubMed Central PMCID:  
465 PMCPMC8351866.
- 466 8. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al.  
467 Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.  
468 *Lancet Infect Dis.* 2017;17(8):873-81. Epub 20170505. doi: 10.1016/S1473-3099(17)30243-  
469 8. PubMed PMID: 28483415; PubMed Central PMCID: PMCPMC5818156.
- 470 9. Global Action for Fungal Infections. GAFFI Roadmap [cited 2023 01-03-2023].  
471 Available from: <https://gaffi.org/roadmap/>.
- 472 10. Bongomin F, Gago S, Oladele RO, Denning DW. Global and Multi-National  
473 Prevalence of Fungal Diseases-Estimate Precision. *J Fungi (Basel).* 2017;3(4). Epub  
474 20171018. doi: 10.3390/jof3040057. PubMed PMID: 29371573; PubMed Central PMCID:  
475 PMCPMC5753159.
- 476 11. Rodrigues ML, Nosanchuk JD. Fungal diseases as neglected pathogens: A wake-up  
477 call to public health officials. *PLoS Negl Trop Dis.* 2020;14(2):e0007964. Epub 20200220.  
478 doi: 10.1371/journal.pntd.0007964. PubMed PMID: 32078635; PubMed Central PMCID:  
479 PMCPMC7032689.
- 480 12. de Hoog GS GJ, Gené J, Ahmed SA, Al-Hatmi AMS, Figueras MJ, Vitale RG. Atlas  
481 of Clinical Fungi. 4 ed. Hilversum: Foundation Atlas of Clinical fungi; 2020.
- 482 13. Global Action for Fungal Infections. Country Fungal Disease Burden [cited 2023 01-  
483 03-2023]. Available from: <https://gaffi.org/media/country-fungal-disease-burdens>.

- 484 14. Tufa TB, Denning DW. The Burden of Fungal Infections in Ethiopia. *J Fungi (Basel)*.  
485 2019;5(4). Epub 20191122. doi: 10.3390/jof5040109. PubMed PMID: 31771096; PubMed  
486 Central PMCID: PMC6958437.
- 487 15. Werkneh S, Orefuwa E, Denning DW. Current situation of fungal diseases in Eritrea.  
488 *Mycoses*. 2022;65(8):806-14. Epub 20220619. doi: 10.1111/myc.13474. PubMed PMID:  
489 35633079; PubMed Central PMCID: PMC9545796.
- 490 16. United Nations Development Programme (UNDP) [cited 2023 01-03-2023].  
491 Available from: <https://www.undp.org/sudan>.
- 492 17. Fahal A, Mahgoub el S, El Hassan AM, Abdel-Rahman ME. Mycetoma in the Sudan:  
493 an update from the Mycetoma Research Centre, University of Khartoum, Sudan. *PLoS Negl*  
494 *Trop Dis*. 2015;9(3):e0003679. Epub 20150327. doi: 10.1371/journal.pntd.0003679. PubMed  
495 PMID: 25816316; PubMed Central PMCID: PMC4376889.
- 496 18. Zijlstra EE, van de Sande WW, Fahal AH. Mycetoma: A Long Journey from Neglect.  
497 *PLoS Negl Trop Dis*. 2016;10(1):e0004244. Epub 20160121. doi:  
498 10.1371/journal.pntd.0004244. PubMed PMID: 26797103; PubMed Central PMCID:  
499 PMC4721668.
- 500 19. The World Factbook - CIA [cited 2023 01-03-2023]. Available from:  
501 <https://www.cia.gov/the-world-factbook/countries/sudan/>.
- 502 20. United Nations, Department of Economic and Social Affairs, Population Division.  
503 *World Population Prospects 2022, Online Edition*. 2022 [cited 2023 01-03-2023]. Available  
504 from: <https://population.un.org/wpp/Download/Standard/MostUsed/>.
- 505 21. The Joint United Nations Programme on HIV/AIDS (UNAIDS). Sudan Fact Sheet.  
506 2021 [cited 2023 01-03-2023]. Available from:  
507 <https://www.unaids.org/en/regionscountries/countries/sudan>.



- 508 22. Denning DW. Minimizing fungal disease deaths will allow the UNAIDS target of  
509 reducing annual AIDS deaths below 500 000 by 2020 to be realized. *Philos Trans R Soc*  
510 *Lond B Biol Sci.* 2016;371(1709). doi: 10.1098/rstb.2015.0468. PubMed PMID: 28080991;  
511 PubMed Central PMCID: PMC5095544.
- 512 23. World Health Organization (WHO). Global tuberculosis report 2020 [cited 2023 01-  
513 03-2023]. Available from: <https://www.who.int/publications/i/item/9789240013131>.
- 514 24. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global  
515 asthma prevalence in adults: findings from the cross-sectional world health survey. *BMC*  
516 *Public Health.* 2012;12:204. Epub 20120319. doi: 10.1186/1471-2458-12-204. PubMed  
517 PMID: 22429515; PubMed Central PMCID: PMC3353191.
- 518 25. Egere U, Shayo E, Ntinginya N, Osman R, Noory B, Mpagama S, et al. Management  
519 of chronic lung diseases in Sudan and Tanzania: how ready are the country health systems?  
520 *BMC Health Serv Res.* 2021;21(1):734. Epub 20210724. doi: 10.1186/s12913-021-06759-9.  
521 PubMed PMID: 34303370; PubMed Central PMCID: PMC8310588.
- 522 26. International Agency for Research on Cancer. Global Cancer Observatory. 2020  
523 [cited 2023 01-03-2023]. Available from:  
524 <https://gco.iarc.fr/today/data/factsheets/populations/729-sudan-fact-sheets.pdf>.
- 525 27. Union for International Cancer Control. Acute Myelogenous Leukemia and Acute  
526 Promyelocytic Leukemia. 2014 Review of Cancer Medicines on the WHO List of Essential  
527 Medicines. [cited 2023 01-03-2023]. Available from: [https://silo.tips/download/acute-  
528 myelogenous-leukemia-including-acute-promyelocytic-leukemia](https://silo.tips/download/acute-myelogenous-leukemia-including-acute-promyelocytic-leukemia).
- 529 28. International Registry in Organ Donation and Transplantation (IRODaT) [cited 2023  
530 01-03-2023]. Available from: <https://www.irodat.org/>.
- 531 29. The World Bank [cited 2023 01-03-2023]. Available from:  
532 <https://data.worldbank.org/country/SD>.

- 533 30. Wharton G, Ali OE, Khalil S, Yagoub H, Mossialos E. Rebuilding Sudan's health  
534 system: opportunities and challenges. *Lancet*. 2020;395(10219):171-3. doi: 10.1016/S0140-  
535 6736(19)32974-5. PubMed PMID: 31954447.
- 536 31. World Health Organization (WHO). Eastern Mediterranean Region Framework for  
537 health information systems and core indicators for monitoring health situation and health  
538 system performance 2016 [cited 2023 01-03-2023]. Available from:  
539 [https://applications.emro.who.int/dsaf/EMROPUB\\_2016\\_EN\\_19169.pdf?ua=1](https://applications.emro.who.int/dsaf/EMROPUB_2016_EN_19169.pdf?ua=1).
- 540 32. Tageldin MA, Nafti S, Khan JA, Nejjar C, Beji M, Mahboub B, et al. Distribution of  
541 COPD-related symptoms in the Middle East and North Africa: results of the BREATHE  
542 study. *Respir Med*. 2012;106 Suppl 2:S25-32. doi: 10.1016/S0954-6111(12)70012-4.  
543 PubMed PMID: 23290701.
- 544 33. Polatli M, Bilgin C, Saylan B, Baslilar S, Toprak E, Ergen H, et al. A cross sectional  
545 observational study on the influence of chronic obstructive pulmonary disease on activities of  
546 daily living: the COPD-Life study. *Tuberk Toraks*. 2012;60(1):1-12. doi: 10.5578/tt.3414.  
547 PubMed PMID: 22554361.
- 548 34. Smith E, Orholm M. Trends and patterns of opportunistic diseases in Danish AIDS  
549 patients 1980-1990. *Scand J Infect Dis*. 1990;22(6):665-72. doi:  
550 10.3109/00365549009027119. PubMed PMID: 2135639.
- 551 35. Serraino D, Puro V, Boumis E, Angeletti C, Girardi E, Petrosillo N, et al.  
552 Epidemiological aspects of major opportunistic infections of the respiratory tract in persons  
553 with AIDS: Europe, 1993-2000. *AIDS*. 2003;17(14):2109-16. doi: 10.1097/00002030-  
554 200309260-00012. PubMed PMID: 14502014.
- 555 36. Kuate MPN, Ekeng BE, Kwizera R, Mandengue C, Bongomin F. Histoplasmosis  
556 overlapping with HIV and tuberculosis in sub-Saharan Africa: challenges and research  
557 priorities. *Ther Adv Infect Dis*. 2021;8:20499361211008675. Epub 20210409. doi:

- 558 10.1177/20499361211008675. PubMed PMID: 33889408; PubMed Central PMCID:  
559 PMCPMC8040546.
- 560 37. Gumaa SA, Ahmed MA, Hassan ME, Hassan AM. A case of African histoplasmosis  
561 from Sudan. *Trans R Soc Trop Med Hyg.* 1988;82(3):503-5. doi: 10.1016/0035-  
562 9203(88)90178-2. PubMed PMID: 3232196.
- 563 38. Mudawi HM, Elamin EM, Baraka OZ, El-Hassan AM. Addison's disease due to  
564 *Histoplasma duboisii* infection of the adrenal glands. *Saudi Med J.* 2008;29(6):904-6.  
565 PubMed PMID: 18521476.
- 566 39. Lortholary O, Gangneux JP, Sitbon K, Lebeau B, de Monbrison F, Le Strat Y, et al.  
567 Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007).  
568 *Clin Microbiol Infect.* 2011;17(12):1882-9. Epub 20110610. doi: 10.1111/j.1469-  
569 0691.2011.03548.x. PubMed PMID: 21668573.
- 570 40. Chen CY, Sheng WH, Tien FM, Lee PC, Huang SY, Tang JL, et al. Clinical  
571 characteristics and treatment outcomes of pulmonary invasive fungal infection among adult  
572 patients with hematological malignancy in a medical centre in Taiwan, 2008-2013. *J*  
573 *Microbiol Immunol Infect.* 2020;53(1):106-14. Epub 20180131. doi:  
574 10.1016/j.jmii.2018.01.002. PubMed PMID: 29449166.
- 575 41. Denning DW, Morgan EF. Quantifying Deaths from Aspergillosis in HIV Positive  
576 People. *J Fungi (Basel).* 2022;8(11). Epub 20221027. doi: 10.3390/jof8111131. PubMed  
577 PMID: 36354898; PubMed Central PMCID: PMC9693143.
- 578 42. Bongomin F. Post-tuberculosis chronic pulmonary aspergillosis: An emerging public  
579 health concern. *PLoS Pathog.* 2020;16(8):e1008742. Epub 20200820. doi:  
580 10.1371/journal.ppat.1008742. PubMed PMID: 32817649; PubMed Central PMCID:  
581 PMC9693143.

- 582 43. Denning DW, Cole DC, Ray A. New estimation of the prevalence of chronic  
583 pulmonary aspergillosis (CPA) related to pulmonary TB - a revised burden for India. *IJID*  
584 *Reg.* 2023;6:7-14. Epub 20221118. doi: 10.1016/j.ijregi.2022.11.005. PubMed PMID:  
585 36568568; PubMed Central PMCID: PMCPMC9772841.
- 586 44. Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis  
587 as a sequel to pulmonary tuberculosis. *Bull World Health Organ.* 2011;89(12):864-72. Epub  
588 20110927. doi: 10.2471/BLT.11.089441. PubMed PMID: 22271943; PubMed Central  
589 PMCID: PMCPMC3260898.
- 590 45. Musa O MA, Elsony A, Eltigani M, Elmahi G, Elawad A, Dawoud O. Prevalence and  
591 Risk Factors of Asthma Symptoms in Adult Sudanese Using a Modified ISAAC.  
592 *International Journal of Science and Research.* 2016;5(2):1153-6.
- 593 46. Ait-Khaled N, Odhiambo J, Pearce N, Adjoh KS, Maesano IA, Benhabyles B, et al.  
594 Prevalence of symptoms of asthma, rhinitis and eczema in 13- to 14-year-old children in  
595 Africa: the International Study of Asthma and Allergies in Childhood Phase III. *Allergy.*  
596 2007;62(3):247-58. doi: 10.1111/j.1398-9995.2007.01325.x. PubMed PMID: 17298341.
- 597 47. Binegdie AB, Meme H, El Sony A, Haile T, Osman R, Miheso B, et al. Chronic  
598 respiratory disease in adult outpatients in three African countries: a cross-sectional study. *Int*  
599 *J Tuberc Lung Dis.* 2022;26(1):18-25. doi: 10.5588/ijtld.21.0362. PubMed PMID: 34969424;  
600 PubMed Central PMCID: PMCPMC8734192.
- 601 48. Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary  
602 aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. *Med*  
603 *Mycol.* 2013;51(4):361-70. Epub 20121204. doi: 10.3109/13693786.2012.738312. PubMed  
604 PMID: 23210682.

- 605 49. Ibrahim SA, Fadl Elmola MA, Karrar ZA, Arabi AM, Abdullah MA, Ali SK, et al.  
606 Cystic fibrosis in Sudanese children: First report of 35 cases. *Sudan J Paediatr.*  
607 2014;14(1):39-44. PubMed PMID: 27493388; PubMed Central PMCID: PMCPMC4949914.
- 608 50. Benatar SR, Keen GA, Du Toit Naude W. Aspergillus hypersensitivity in asthmatics  
609 in Cape Town. *Clin Allergy.* 1980;10(3):285-91. doi: 10.1111/j.1365-2222.1980.tb02109.x.  
610 PubMed PMID: 7418186.
- 611 51. Al-Mobeireek AF, El-Rab M, Al-Hedaithy SS, Alasali K, Al-Majed S, Joharjy I.  
612 Allergic bronchopulmonary mycosis in patients with asthma: period prevalence at a  
613 university hospital in Saudi Arabia. *Respir Med.* 2001;95(5):341-7. doi:  
614 10.1053/rmed.2001.1047. PubMed PMID: 11392574.
- 615 52. Kwizera R, Bongomin F, Olum R, Meya DB, Worodria W, Bwanga F, et al. Fungal  
616 asthma among Ugandan adult asthmatics. *Medical Mycology.* 2021;59(9):923-33. doi:  
617 10.1093/mmy/myab023.
- 618 53. Singh V. Fungal Rhinosinusitis: Unravelling the Disease Spectrum. *J Maxillofac Oral*  
619 *Surg.* 2019;18(2):164-79. Epub 20190128. doi: 10.1007/s12663-018-01182-w. PubMed  
620 PMID: 30996535; PubMed Central PMCID: PMCPMC6441414.
- 621 54. Said SA, McHembe MD, Chalya PL, Rambau P, Gilyoma JM. Allergic rhinitis and its  
622 associated co-morbidities at Bugando Medical Centre in Northwestern Tanzania; A  
623 prospective review of 190 cases. *BMC Ear Nose Throat Disord.* 2012;12:13. Epub 20121108.  
624 doi: 10.1186/1472-6815-12-13. PubMed PMID: 23136895; PubMed Central PMCID:  
625 PMCPMC3515478.
- 626 55. Veress B, Malik OA, el-Tayeb AA, el-Daoud S, Mahgoub ES, el-Hassan AM. Further  
627 observations on the primary paranasal aspergillus granuloma in the Sudan: a morphological  
628 study of 46 cases. *Am J Trop Med Hyg.* 1973;22(6):765-72. doi: 10.4269/ajtmh.1973.22.765.  
629 PubMed PMID: 4200814.

- 630 56. Ahmed SAO, Mustafa OME. Clinical features of Fungal Rhinosinusitis in Sudan. A  
631 study of 440 cases. PAN Arab Journal of Rhinology. 2013;3(1).
- 632 57. Mahgoub ES, Ismail MAI and Gabr A.. Fungal Sinusitis: Sudanese Experience.  
633 Austin J Otolaryngol. 2016;3(4):1085.
- 634 58. Montravers P, Mira JP, Gangneux JP, Leroy O, Lortholary O, AmarCand study g. A  
635 multicentre study of antifungal strategies and outcome of *Candida* spp. peritonitis in  
636 intensive-care units. Clin Microbiol Infect. 2011;17(7):1061-7. Epub 20101019. doi:  
637 10.1111/j.1469-0691.2010.03360.x. PubMed PMID: 20825438.
- 638 59. Mushi MF, Olum R, Bongomin F. Prevalence, antifungal susceptibility and etiology  
639 of vulvovaginal candidiasis in sub-Saharan Africa: a systematic review with meta-analysis  
640 and meta-regression. Med Mycol. 2022;60(7). doi: 10.1093/mmy/myac037. PubMed PMID:  
641 35781514.
- 642 60. Kafi SK, Mohamed AO, Musa HA. Prevalence of sexually transmitted diseases (STD)  
643 among women in a suburban Sudanese community. Ups J Med Sci. 2000;105(3):249-53. doi:  
644 10.3109/2000-1967-179. PubMed PMID: 11261611.
- 645 61. Nemery HM. Phenotypic Characterization of Vaginal Candidiasis in Sudanese  
646 Pregnant Women African Journal of Medical Sciences. 2019;4(4).
- 647 62. Abdelaziz ZA, Ibrahim ME, Bilal NE, Hamid ME. Vaginal infections among  
648 pregnant women at Omdurman Maternity Hospital in Khartoum, Sudan. J Infect Dev Ctrie.  
649 2014;8(4):490-7. Epub 20140415. doi: 10.3855/jidc.3197. PubMed PMID: 24727516.
- 650 63. Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of  
651 recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis.  
652 2018;18(11):e339-e47. Epub 20180802. doi: 10.1016/S1473-3099(18)30103-8. PubMed  
653 PMID: 30078662.

- 654 64. Lynch JB, Husband AD. Subcutaneous phycomycetosis. *J Clin Pathol.*  
655 1962;15(2):126-32. doi: 10.1136/jcp.15.2.126. PubMed PMID: 14467579; PubMed Central  
656 PMCID: PMCPMC480359.
- 657 65. Fischer N, Ruef C, Ebnother C, Bachli EB. Rhinofacial *Conidiobolus coronatus*  
658 infection presenting with nasal enlargement. *Infection.* 2008;36(6):594-6. Epub 20081108.  
659 doi: 10.1007/s15010-008-8056-5. PubMed PMID: 18998052.
- 660 66. Mohammed SA, Abdelsatir AA, Abdellatif M, Suliman SH, Elbasheer OMI, Abdalla  
661 AR, et al. Challenging Presentations of Seven Cases of Gastrointestinal Basidiobolomycosis  
662 in Sudan: Clinical Features, Histology, Imaging, and Recommendations. *J Lab Physicians.*  
663 2020;12(4):281-4. Epub 20201230. doi: 10.1055/s-0040-1721149. PubMed PMID:  
664 33390679; PubMed Central PMCID: PMCPMC7773445.
- 665 67. Taha S MA, Hassan L, EL Hassan AM, Mustafa G, Yaseen DE. Gastrointestinal  
666 Basidiobolomycosis Mimicking Colon Cancer in a Sudanese Patient. 2011;6(1). doi:  
667 10.4314/sjms.v6i1.67277.
- 668 68. Gangneux JP, Bougnoux ME, Hennequin C, Godet C, Chandenier J, Denning DW, et  
669 al. An estimation of burden of serious fungal infections in France. *J Mycol Med.*  
670 2016;26(4):385-90. Epub 20161122. doi: 10.1016/j.mycmed.2016.11.001. PubMed PMID:  
671 27887809.
- 672 69. Fahal A, Mahgoub el S, El Hassan AM, Abdel-Rahman ME, Alshambaty Y, Hashim  
673 A, et al. A new model for management of mycetoma in the Sudan. *PLoS Negl Trop Dis.*  
674 2014;8(10):e3271. Epub 20141030. doi: 10.1371/journal.pntd.0003271. PubMed PMID:  
675 25356640; PubMed Central PMCID: PMCPMC4214669.
- 676 70. Abbott P. Mycetoma in the Sudan. *Trans R Soc Trop Med Hyg.* 1956;50(1):11-24.  
677 doi: 10.1016/0035-9203(56)90004-9. PubMed PMID: 13299347.

- 678 71. Hassan R, Cano J, Fronterre C, Bakhiet S, Fahal A, Deribe K, et al. Estimating the  
679 burden of mycetoma in Sudan for the period 1991-2018 using a model-based geostatistical  
680 approach. *PLoS Negl Trop Dis*. 2022;16(10):e0010795. Epub 20221014. doi:  
681 10.1371/journal.pntd.0010795. PubMed PMID: 36240229; PubMed Central PMCID:  
682 PMCPMC9604875.
- 683 72. Gumaa SA. Sporotrichosis in Sudan. *Trans R Soc Trop Med Hyg*. 1978;72(6):637-40.  
684 doi: 10.1016/0035-9203(78)90020-2. PubMed PMID: 734721.
- 685 73. Mahgoub ES. Ringworm infection among Sudanese school children. *Trans R Soc*  
686 *Trop Med Hyg*. 1968;62(2):263-8. doi: 10.1016/0035-9203(68)90167-3. PubMed PMID:  
687 4230638.
- 688 74. Ahmed ASAA, Ahmed MAI, Abdelrahma NAM, Adam NKA, Abdel-aziz DS,  
689 Ahmed ABM. Prevalence of tinea capitis among school age children in eastern Sudan *J*  
690 *Bacteriol Mycol Open Access*. 2021;9(2):94–7. doi: DOI: 10.15406/jbmoa.2021.09.00303.
- 691 75. Bongomin F, Olum R, Nsenga L, Namusobya M, Russell L, de Sousa E, et al.  
692 Estimation of the burden of tinea capitis among children in Africa. *Mycoses*. 2021;64(4):349-  
693 63. Epub 20201209. doi: 10.1111/myc.13221. PubMed PMID: 33251631.
- 694 76. Zaki SM, Denning DW. Serious fungal infections in Egypt. *Eur J Clin Microbiol*  
695 *Infect Dis*. 2017;36(6):971-4. Epub 20170217. doi: 10.1007/s10096-017-2929-4. PubMed  
696 PMID: 28213689.
- 697 77. Xu H, Li L, Huang WJ, Wang LX, Li WF, Yuan WF. Invasive pulmonary  
698 aspergillosis in patients with chronic obstructive pulmonary disease: a case control study  
699 from China. *Clin Microbiol Infect*. 2012;18(4):403-8. Epub 20111025. doi: 10.1111/j.1469-  
700 0691.2011.03503.x. PubMed PMID: 22023558.



- 701 78. Matee MI, Scheutz F, Moshy J. Occurrence of oral lesions in relation to clinical and  
702 immunological status among HIV-infected adult Tanzanians. *Oral Dis.* 2000;6(2):106-11.  
703 doi: 10.1111/j.1601-0825.2000.tb00110.x. PubMed PMID: 10702788.
- 704 79. Buchacz K, Baker RK, Palella FJ, Jr., Chmiel JS, Lichtenstein KA, Novak RM, et al.  
705 AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. *AIDS.*  
706 2010;24(10):1549-59. doi: 10.1097/QAD.0b013e32833a3967. PubMed PMID: 20502317.
- 707 80. Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses  
708 worldwide. *Mycoses.* 2008;51 Suppl 4:2-15. doi: 10.1111/j.1439-0507.2008.01606.x.  
709 PubMed PMID: 18783559.
- 710 81. Magzoub OS. Tinea Capitis: Frequency and Clinical Manifestations among Children  
711 in Khartoum Dermatological Hospital, Sudan. *Merit Research Journal of Medicine and*  
712 *Medical Sciences.* 2022;10(1):1-8. doi: <https://doi.org/10.5281/zenodo.5910631>.
- 713 82. Fuller LC, Barton RC, Mohd Mustapa MF, Proudfoot LE, Punjabi SP, Higgins EM.  
714 British Association of Dermatologists' guidelines for the management of tinea capitis 2014.  
715 *Br J Dermatol.* 2014;171(3):454-63. doi: 10.1111/bjd.13196. PubMed PMID: 25234064.
- 716 83. Badiane AS, Ramarozatovo LS, Doumbo SN, Dorkenoo AM, Mandengue C,  
717 Dunaïski CM, et al. Diagnostic capacity for cutaneous fungal diseases in the african  
718 continent. *Int. J. Dermatol.* 2023. (Accepted)
- 719 84. Brown L, Kamwiziku G, Oladele RO, Burton MJ, Prajna NV, Leitman TM, et al. The  
720 Case for Fungal Keratitis to Be Accepted as a Neglected Tropical Disease. *J Fungi (Basel).*  
721 2022;8(10). Epub 20221005. doi: 10.3390/jof8101047. PubMed PMID: 36294612; PubMed  
722 Central PMCID: PMC9605065.
- 723 85. Burton MJ, Pithuwa J, Okello E, Afwamba I, Onyango JJ, Oates F, et al. Microbial  
724 keratitis in East Africa: why are the outcomes so poor? *Ophthalmic Epidemiol.*

- 725 2011;18(4):158-63. doi: 10.3109/09286586.2011.595041. PubMed PMID: 21780874;
- 726 PubMed Central PMCID: PMCPMC3670402.
- 727 86. EL Shabrawy RM, El Badawy NEL, Harb AW. The incidence of fungal keratitis in  
728 Zagazig University Hospitals, Egypt and the value of direct microscopy and PCR technique  
729 in rapid diagnosis. 2013; 3 (4): doi: 10.5799/ahinjs022013040106. 2013;3(4):186-91. doi:  
730 10.5799/ahinjs.02.2013.04.0106.
- 731 87. lakho KA, Mohamed Ali AB. Pattern of eye diseases at tertiary eye hospital in Sudan  
732 (Makah Eye Hospital, Khartoum). *Albasar Int J Ophthalmol*. 2015;3:15-158.
- 733 88. Qiu S, Zhao GQ, Lin J, Wang X, Hu LT, Du ZD, et al. Natamycin in the treatment of  
734 fungal keratitis: a systematic review and Meta-analysis. *Int J Ophthalmol*. 2015;8(3):597-602.  
735 Epub 20150618. doi: 10.3980/j.issn.2222-3959.2015.03.29. PubMed PMID: 26086015;  
736 PubMed Central PMCID: PMCPMC4458670.
- 737 89. Global Action For Fungal Infections. Antifungal Drug Maps [cited 2023 01-03-  
738 2023]. Available from: <https://gaffi.org/antifungal-drug-maps/>.
- 739 90. Orefuwa E, Gangneux JP, Denning DW. The challenge of access to refined fungal  
740 diagnosis: An investment case for low- and middle-income countries. *J Mycol Med*.  
741 2021;31(2):101140. Epub 20210420. doi: 10.1016/j.mycmed.2021.101140. PubMed PMID:  
742 33971531.
- 743 91. Hassanain SA, Edwards JK, Venables E, Ali E, Adam K, Hussien H, et al. Conflict  
744 and tuberculosis in Sudan: a 10-year review of the National Tuberculosis Programme, 2004-  
745 2014. *Confl Health*. 2018;12:18. Epub 20180516. doi: 10.1186/s13031-018-0154-0. PubMed  
746 PMID: 29785203; PubMed Central PMCID: PMCPMC5954449.
- 747 92. Mahgoub ES, el-Hassan AM. Pulmonary aspergillosis caused by *Aspergillus flavus*.  
748 *Thorax*. 1972;27(1):33-7. doi: 10.1136/thx.27.1.33. PubMed PMID: 4622807; PubMed  
749 Central PMCID: PMCPMC472456.

- 750 93. Baraka AA, Alabid SA, Mohammed MA, Ahmed NM. Frequency of Pulmonary  
751 Aspergillosis Among Clinically Suspected and Under Treatment Tuberculosis Patients ,  
752 Khartoum State , Sudan. *Al-Kindy College Medical Journal*. 2022;17(3):180-4. doi:  
753 <https://doi.org/10.47723/kcmj.v17i3.430>.
- 754 94. Denning DW. Diagnosing pulmonary aspergillosis is much easier than it used to be: a  
755 new diagnostic landscape. *Int J Tuberc Lung Dis*. 2021;25(7):525-36. doi:  
756 10.5588/ijtld.21.0053. PubMed PMID: 34183097.
- 757 95. Ismail M, Gabr A, Zhou S, Mahgoub E, Ahmed S. P346 Pulmonary fungal infection  
758 in Sudan, a retrospective study from the Mycology Reference Laboratory. *Medical*  
759 *Mycology*. 2022;60(Supplement\_1). doi: 10.1093/mmy/myac072.P346.
- 760 96. Rapeport WG, Ito K, Denning DW. The role of antifungals in the management of  
761 patients with severe asthma. *Clinical and Translational Allergy*. 2020;10(1):46. doi:  
762 10.1186/s13601-020-00353-8.
- 763 97. Kamwiziku GK, Makangara JC, Orefuwa E, Denning DW. Serious fungal diseases in  
764 Democratic Republic of Congo - Incidence and prevalence estimates. *Mycoses*.  
765 2021;64(10):1159-69. Epub 20210625. doi: 10.1111/myc.13339. PubMed PMID: 34133799.
- 766 98. Osman R AK, ElSony A. Factors associated with uncontrolled asthma among  
767 Sudanese adult patients. *J Pan Afr Thorac Soc*. 2021;2(2):85-93. doi: DOI:  
768 10.25259/JPATS\_22\_2020.
- 769 99. van Gemert F, van der Molen T, Jones R, Chavannes N. The impact of asthma and  
770 COPD in sub-Saharan Africa. *Prim Care Respir J*. 2011;20(3):240-8. doi:  
771 10.4104/pcrj.2011.00027. PubMed PMID: 21509418; PubMed Central PMCID:  
772 PMC6549843.
- 773 100. Verweij PE, Bruggemann RJM, Azoulay E, Bassetti M, Blot S, Buil JB, et al.  
774 Taskforce report on the diagnosis and clinical management of COVID-19 associated

- 775 pulmonary aspergillosis. *Intensive Care Med.* 2021;47(8):819-34. Epub 20210623. doi:  
776 10.1007/s00134-021-06449-4. PubMed PMID: 34160631; PubMed Central PMCID:  
777 PMCPMC8220883.
- 778 101. World Health Organization. WHO fungal priority pathogens list to guide research,  
779 development and public health action 2022 [cited 2023 01-03-2023]. Available from:  
780 <https://www.who.int/publications/i/item/9789240060241>.
- 781 102. Douglas AP, Smibert OC, Bajel A, Halliday CL, Lavee O, McMullan B, et al.  
782 Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021.  
783 *Intern Med J.* 2021;51 Suppl 7:143-76. doi: 10.1111/imj.15591. PubMed PMID: 34937136.
- 784 103. Bateman M, Oladele R, Kolls JK. Diagnosing *Pneumocystis jirovecii* pneumonia: A  
785 review of current methods and novel approaches. *Med Mycol.* 2020;58(8):1015-28. doi:  
786 10.1093/mmy/myaa024. PubMed PMID: 32400869; PubMed Central PMCID:  
787 PMCPMC7657095.
- 788 104. Oladele RO, Osaigbovo, II, Akanmu AS, Adekanmbi OA, Ekeng BE, Mohammed Y,  
789 et al. Prevalence of Histoplasmosis among Persons with Advanced HIV Disease, Nigeria.  
790 *Emerg Infect Dis.* 2022;28(11):2261-9. doi: 10.3201/eid2811.220542. PubMed PMID:  
791 36286009; PubMed Central PMCID: PMCPMC9622240.
- 792 105. Bongomin F, Ekeng BE, Kibone W, Nsenga L, Olum R, Itam-Eyo A, et al. Invasive  
793 Fungal Diseases in Africa: A Critical Literature Review. *J Fungi (Basel).* 2022;8(12). Epub  
794 20221122. doi: 10.3390/jof8121236. PubMed PMID: 36547569; PubMed Central PMCID:  
795 PMCPMC9853333.
- 796 106. Badri AM, Sherfi SA. First Detection of Emergent Fungal Pathogen *Candida auris* in  
797 Khartoum State, Sudan. *J Biomed Sci & Res.* 2019;(1). doi:  
798 DOI:10.34297/AJBSR.2019.06.000982.
- 799